

Accepted Manuscript

The twin drug approach for novel nicotinic acetylcholine receptor ligands

Isabelle Tomassoli, Daniela Gündisch


PII: S0968-0896(15)00528-3
DOI: <http://dx.doi.org/10.1016/j.bmc.2015.06.034>
Reference: BMC 12390

To appear in: *Bioorganic & Medicinal Chemistry*

Received Date: 30 March 2015
Revised Date: 30 May 2015
Accepted Date: 10 June 2015

Please cite this article as: Tomassoli, I., Gündisch, D., The twin drug approach for novel nicotinic acetylcholine receptor ligands, *Bioorganic & Medicinal Chemistry* (2015), doi: <http://dx.doi.org/10.1016/j.bmc.2015.06.034>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



The twin drug approach for novel nicotinic acetylcholine receptor ligands

Isabelle Tomassoli and Daniela Gündisch*

Department of Pharmaceutical Sciences, The Daniel K. Inouye College of Pharmacy, University of Hawai'i at Hilo, Hilo, HI, U.S.A.

ABSTRACT

The association of two pharmacophoric entities generates so-called "twin drugs" or dimer derivatives. We applied this approach for the design of a small compound library for the interaction with $\alpha 4\beta 2^*$ nicotinic acetylcholine receptors (nAChRs). In this compound series, the nAChR ligand *N,N*-dimethyl-2-(pyridin-3-yloxy)ethan-1-amine **9** served as one pharmacological entity and it was initially kept constant as one part of the "twin" compound. "Twin" compounds with identical or non-identical entities using the "no linker mode" or "overlap" mode were synthesized and evaluated for their nAChR affinities. Compound **17a** showed the highest affinity for the $\alpha 4\beta 2^*$ nAChR subtype ($K_i = 0.188$ nM) and its (di)fluoro analogs could retain nanomolar affinities, when replacing pyridine as the hydrogen bond acceptor system by mono- or difluorophenyls. The "twin drug" approach proved to provide compounds with high affinity and subtype selectivity for $\alpha 4\beta 2^*$ nAChRs.

Keywords:

Twin drugs

Nicotinic acetylcholine receptor

nAChR

Structure-activity relationship

3D QSAR pharmacophore

Abbreviations: ADME, absorption/distribution/metabolism/excretion; BBB, blood-brain barrier; CD₃OD, tetradeuteromethanol; CDCl₃, deuteriochloroform; CH₂Cl₂, dichloromethane; ClogD, distribution coefficient; ClogP, calculated partition coefficient; CNS, central nervous system; DAT, dopamine transporter; DCC, *N,N'*-dicyclohexylcarbodiimide; DIAD, diisopropyl

Download English Version:

<https://daneshyari.com/en/article/10583544>

Download Persian Version:

<https://daneshyari.com/article/10583544>

[Daneshyari.com](https://daneshyari.com)